These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 34404463)

  • 21. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
    Poddubnyy D; Hammel L; Heyne M; Veit J; Jentzsch C; Baraliakos X
    BMJ Open; 2020 Sep; 10(9):e039059. PubMed ID: 32998926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
    Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
    Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
    J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and clinical efficacy of the secretome of stressed peripheral blood mononuclear cells in patients with diabetic foot ulcer-study protocol of the randomized, placebo-controlled, double-blind, multicenter, international phase II clinical trial MARSYAS II.
    Gugerell A; Gouya-Lechner G; Hofbauer H; Laggner M; Trautinger F; Almer G; Peterbauer-Scherb A; Seibold M; Hoetzenecker W; Dreschl C; Mildner M; Ankersmit HJ
    Trials; 2021 Jan; 22(1):10. PubMed ID: 33407796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
    Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy and safety of leflunomide versus placebo combined with basic prednisone therapy in patients with active disease phase of Takayasu arteritis: study protocol for a randomized, double-blinded controlled trial (Takayasu arteritis clinical trial in China: TACTIC).
    Sun Y; Wu B; Zhang W; Ma L; Kong X; Chen H; Jiang L
    Ther Adv Chronic Dis; 2023; 14():20406223231158567. PubMed ID: 36895331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
    Hueber W; Sands BE; Lewitzky S; Vandemeulebroecke M; Reinisch W; Higgins PD; Wehkamp J; Feagan BG; Yao MD; Karczewski M; Karczewski J; Pezous N; Bek S; Bruin G; Mellgard B; Berger C; Londei M; Bertolino AP; Tougas G; Travis SP;
    Gut; 2012 Dec; 61(12):1693-700. PubMed ID: 22595313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
    Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M
    Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
    N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
    Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
    N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
    Bhat RM; Leelavathy B; Aradhya SS; Gopal MG; Pratap DV; Mubashir M; Srinivas P; Pande SY; Thavkar AS
    Indian Dermatol Online J; 2017; 8(1):16-24. PubMed ID: 28217466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
    Cai L; Zhang JZ; Yao X; Gu J; Liu QZ; Zheng M; Zhang SF; Xu JH; Li CX; Cheng H; Guo Q; Pan WL; Li SQ; Li RY; Guo ZP; Song ZQ; Li SS; Dong XQ; Wang L; Fu R; Regnault P; Charef P; Mazur R; Patekar M
    Chin Med J (Engl); 2020 Nov; 133(22):2665-2673. PubMed ID: 33060370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.
    Langford CA; Cuthbertson D; Ytterberg SR; Khalidi N; Monach PA; Carette S; Seo P; Moreland LW; Weisman M; Koening CL; Sreih AG; Spiera R; McAlear CA; Warrington KJ; Pagnoux C; McKinnon K; Forbess LJ; Hoffman GS; Borchin R; Krischer JP; Merkel PA;
    Arthritis Rheumatol; 2017 Apr; 69(4):837-845. PubMed ID: 28133925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis.
    Raine C; Stapleton PP; Merinopoulos D; Maw WW; Achilleos K; Gayford D; Mapplebeck S; Mackerness C; Schofield P; Dasgupta B
    Int J Rheum Dis; 2018 Jan; 21(1):285-291. PubMed ID: 28791802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
    Stone JH; Han J; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Unizony SH; Bao M;
    Lancet Rheumatol; 2021 May; 3(5):e328-e336. PubMed ID: 38279390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.